<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24538" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Left Ventricular Assist Devices</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaidya</surname>
            <given-names>Yash</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Riaz</surname>
            <given-names>Sana</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dhamoon</surname>
            <given-names>Amit S.</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yash Vaidya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sana Riaz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amit Dhamoon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24538.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Heart failure (HF) is a frequent cause of inpatient admissions. The Framingham study in 1993 described the risk factors for heart failure. A recent study showed results of the five-year study showed an improved survival rate of 58% with the HeartMate 3 (vs. 44% with the HeartMate II). The American Heart Association reported the prevalence of HF to be 5.1 million in the United States in 2006. The worldwide prevalence has been estimated to be 23 million. HF can be categorized based on the left ventricular ejection fraction (LVEF) into systolic and diastolic HF. The former group includes patients with LVEF less than or equal to 40%, also termed heart failure with reduced ejection fraction (HFrEF). Heart failure with preserved ejection fraction (HFpEF) includes those with LVEF greater than or equal to 40%. This activity reviews the role of LVADs, their indications, and contraindications and highlights the role of the interprofessional team in the management of patients with end-stage cardiac disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the indications of LVAD.</p></list-item><list-item><p>Review the contraindications for LVAD.</p></list-item><list-item><p>Summarize the complications of an LVAD.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients needing an LVAD.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24538&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24538">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24538.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Heart failure (HF) is a frequent cause of inpatient admissions. The Framingham study in 1993 described the risk factors for heart failure and showed unacceptably high five-year mortality rates of 25% in men and 38% in women <xref ref-type="bibr" rid="article-24538.r1">[1]</xref>. The American Heart Association reported the prevalence of HF to be 5.1 million in the United States in 2006 <xref ref-type="bibr" rid="article-24538.r2">[2]</xref>. The worldwide prevalence has been estimated to be 23 million <xref ref-type="bibr" rid="article-24538.r3">[3]</xref>.</p>
        <p>HF can be categorized based on the left ventricular ejection fraction (LVEF) into systolic and diastolic HF. The former group includes patients with LVEF less than or equal to 40%, also termed heart failure with reduced ejection fraction (HFrEF). Heart failure with preserved ejection fraction (HFpEF) includes those with LVEF greater than or equal to 40%.&#x000a0;</p>
        <p>The multiple modalities of treatment available to treat HF include but are not limited to lifestyle modifications, pharmacologic agents, device therapies such as implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT). At times, failure to improve could necessitate short-term mechanical circulatory support with the use of an intra-aortic balloon pump (IABP) or even extracorporeal membrane oxygenation (ECMO). However, a large population of patients continues to have advanced heart failure with worsening LVEF despite maximal therapy.</p>
        <p>Circulatory support with the use of a left ventricular assist device (LVAD) is an emerging field. The landmark REMATCH trial that compared LVADs with optimal medical therapy in class IV HF patients found a 48% reduction in mortality from any cause <xref ref-type="bibr" rid="article-24538.r4">[4]</xref>. There was also a significant increase in the survival rates at one year (52% versus 25%) and two years (23% versus 8%). The definitive treatment for advanced HF (class II and IV) is cardiac transplantation <xref ref-type="bibr" rid="article-24538.r5">[5]</xref>. However, with the limited number of donor hearts available, LVADs are life-saving.</p>
      </sec>
      <sec id="article-24538.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>The basic design of LVADs since their inception has stayed similar. The inlet cannula is placed in the apex of the left ventricle (LV). The blood subsequently enters the pump, the structure of which has undergone significant changes over time. The outflow graft then leads to the ascending (most common) or descending aorta <xref ref-type="bibr" rid="article-24538.r6">[6]</xref>.</p>
        <p>The first-generation LVADs were approved by the United States Food and Drug Administration (FDA) for clinical use in 1994. These were pulsatile-flow LVADs used for circulatory support as a bridge to transplantation (BTT) for patients awaiting donor's hearts. However, the second and third-generation continuous-flow devices have had modifications in structure and function, with improved durability, which has expanded their use as destination therapy (DT) in patients who are not eligible for cardiac transplantation <xref ref-type="bibr" rid="article-24538.r7">[7]</xref><xref ref-type="bibr" rid="article-24538.r8">[8]</xref>. The eighth annual report&#x000a0;of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)&#x000a0;in 2017 showed one-year and two-year survival rates with currently used continuous-flow devices to be greater than 80% and greater than 70%, respectively <xref ref-type="bibr" rid="article-24538.r9">[9]</xref>.&#x000a0;</p>
        <p>
<bold>First-Generation Devices</bold>
</p>
        <p>These were pulsatile volume-displacement pumps. The Heartmate I (HM I) was used in the REMATCH trial and underwent many modifications but is no longer manufactured. Another of its generation, the Novacor also, is now obsolete due to a high risk of stroke. The Thoratec paracorporeal ventricular assist device (PVAD) is still manufactured but rarely used. The first-generation devices required significant surgical dissection for placement and were suited to those with a large body habitus. They also had a high rate of infection at the external lead. Also, the pump was audible and caused discomfort. These limitations resulted in the discontinuation of their use.</p>
        <p>
<bold>Second-Generation Devices&#x000a0;</bold>
</p>
        <p>These are continuous flow devices that use axial flow pumps. The Heartmate II (HM II) and Jarvik 2000 are the two most commonly used devices, with the latter characterized by outflow graft anastomosis to the descending aorta. The rotor is the only moving part of these devices, making them more durable. These devices are smaller and easier to implant. They are quieter and also associated with lower rates of driveline infection than first-generation devices. The sixth INTERMACS annual report showed that, since 2010, all patients receiving DT had continuous flow devices <xref ref-type="bibr" rid="article-24538.r10">[10]</xref>.</p>
        <p>
<bold>Third Generation Devices</bold>
</p>
        <p>These are continuous flow centrifugal pumps, of which the HeartWare and Heartmate 3 are the most popular. They are designed for long durability (5 to 10 years), easy surgical placement, and low risk of hemolysis or thrombosis. Smaller devices are currently in the testing phase.</p>
        <p>
<bold>Biventricular Assist Device (BiVAD)</bold>
</p>
        <p>This device is used for patients with either biventricular failure&#x000a0;or right ventricular failure associated with left ventricular disease. The total artificial heart (TAH) has been a revolution. The SynCardia TAH is the most widely used TAH, with over 1600 patients benefiting.</p>
      </sec>
      <sec id="article-24538.s4" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>Bridge-to-Transplantation</bold>
</p>
        <p>The purpose of&#x000a0;Bridge-to-Transplantation (BTT) is to&#x000a0;provide circulatory support to transplant-eligible patients with HFrEF until a donor's heart becomes available.</p>
        <p>
<bold>Destination therapy</bold>
</p>
        <p>Destination therapy (DT)&#x000a0;is used in patients with HFrEF who are ineligible for cardiac transplantation. The newer devices with improved durability have shown increased survival rates in this category of patients.</p>
        <p>
<bold>Bridge-to-the-Decision</bold>
</p>
        <p>LVADs have been used as a temporary measure in patients with end-organ dysfunction due to HF (relative contraindication to transplantation). Stabilization of hemodynamics with improvement in renal function, nutritional status, and reduction in pulmonary hypertension can help make them transplant-eligible.</p>
        <p>
<bold>Bridge-to-Recovery</bold>
</p>
        <p>Bridge-to-Recovery (BTR)<bold>&#x000a0;</bold>provides temporary ventricular support in some HF patients and has been shown to improve myocardial function and promote recovery <xref ref-type="bibr" rid="article-24538.r11">[11]</xref>.&#x000a0;</p>
        <p>Strong indications for either BTT, DT, or BTR are as follows. All must be applicable <xref ref-type="bibr" rid="article-24538.r12">[12]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>NYHA class IV for 60 to 90 days</p>
          </list-item>
          <list-item>
            <p>Maximal tolerated medical therapy and certified respiratory therapy/implantable cardioverter-defibrillator if indicated</p>
          </list-item>
          <list-item>
            <p>Chronic dependence on inotropic agents</p>
          </list-item>
          <list-item>
            <p>LVEF&#x000a0;less than 25%</p>
          </list-item>
          <list-item>
            <p>Pulmonary capillary wedge pressure greater than or equal to 20 mmHg</p>
          </list-item>
          <list-item>
            <p>Systolic BP less than or equal to 80 to 90 mmHg or cardiac index less than or equal to 2 L/min/m2, evidence of declining renal or right ventricular function</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24538.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>These have been well summarized in a review that was derived from entry criteria in several studies <xref ref-type="bibr" rid="article-24538.r12">[12]</xref>.</p>
        <list list-type="bullet">
          <list-item>
            <p>Right, ventricular dysfunction: Either primarily or right heart failure, not secondary to left heart failure. Improper function of the right ventricle leads to insufficient filling of the left heart, which may lead to inadequate inflow in the device and, ultimately, device malfunction.</p>
          </list-item>
          <list-item>
            <p>Acute cardiogenic shock with a neurological compromise: Without adequate higher functions, LVAD placement is not recommended as it would only increase morbidity and decrease the quality of life.</p>
          </list-item>
          <list-item>
            <p>Coexisting severe terminal comorbidity: Severe renal, pulmonary, liver, or neurological disease or evidence of advanced metastatic cancer are considered contraindications.</p>
          </list-item>
          <list-item>
            <p>Bleeding: Active bleeding or thrombocytopenia (platelet count less than 50000 x 10 per L) or confirmed heparin-induced thrombocytopenia. Not just the bleeding but also the inability to be placed on anticoagulation makes this a contraindication.</p>
          </list-item>
          <list-item>
            <p>Anatomical factors: Hypertrophic cardiomyopathy or a large ventricular septal defect are a hindrance to device placement and function.</p>
          </list-item>
          <list-item>
            <p>Technical limitations: Body surface area less than 1.2 to 1.5 m2 or any other factor.</p>
          </list-item>
          <list-item>
            <p>Social considerations: LVAD management requires a high degree of patient compliance, which necessitates adequate psychological function to comply with medications and device maintenance. It also requires family education in interpreting basic functions and alarms. Thus, any difficulty posed by such factors could pose a contraindication to LVAD placement.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24538.s6" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Hematological</bold>
</p>
        <p>Bleeding is the most common complication, occurring in both the perioperative period as well as later due to the need for anticoagulation with warfarin <xref ref-type="bibr" rid="article-24538.r13">[13]</xref>. Cardiopulmonary bypass perioperatively alters the coagulation cascades and impairs the normal clotting mechanism, leading to bleeding. Also, bleeding has been attributed to the association of acquired von Willebrand disease in LVAD patients, typically more than a week after the procedure&#x000a0;<xref ref-type="bibr" rid="article-24538.r14">[14]</xref>. This is usually reversible if the LVAD is removed <xref ref-type="bibr" rid="article-24538.r15">[15]</xref>.</p>
        <p>Bleeding may occur due to a leak at the pump site from polyester grafts in the conduits, the gastrointestinal mucosal surfaces, and intracranial vessels. The target INR in outpatients is usually 1.5 to 2.5 <xref ref-type="bibr" rid="article-24538.r16">[16]</xref>.&#x000a0;</p>
        <p>Thrombosis is another significant hematological complication Patients may develop pump thrombosis, embolic events, or stroke. It is usually due to subtherapeutic anticoagulation, atrial fibrillation, or infection that predisposes to a hypercoagulative state.</p>
        <p>Hemolysis is another possibility due to technical complications involving the design of the pump, malpositioned cannulae, or the development of heparin-induced thrombocytopenia and pump thrombosis&#x000a0;<xref ref-type="bibr" rid="article-24538.r17">[17]</xref>.</p>
        <p>
<bold>Right Heart Failure</bold>
</p>
        <p>Anatomic changes following LVAD placement cause right ventricular geometric alterations. With left ventricular (LV) unloading, the septum shifts to the left. The increased cardiac output from the LVAD results in an increased venous return to the right ventricle, which now has improved compliance. However, in patients with chronic heart failure, there is pre-existing pulmonary hypertension. This can result in right ventricular (RV) failure <xref ref-type="bibr" rid="article-24538.r18">[18]</xref><xref ref-type="bibr" rid="article-24538.r19">[19]</xref><xref ref-type="bibr" rid="article-24538.r18">[18]</xref>.</p>
        <p>This may necessitate the use of milrinone to reduce pulmonary vascular resistance or epoprostenol as a selective pulmonary vasodilator <xref ref-type="bibr" rid="article-24538.r20">[20]</xref><xref ref-type="bibr" rid="article-24538.r21">[21]</xref><xref ref-type="bibr" rid="article-24538.r20">[20]</xref>. In some circumstances, the use of RV mechanical support or ECMO may be required <xref ref-type="bibr" rid="article-24538.r22">[22]</xref><xref ref-type="bibr" rid="article-24538.r23">[23]</xref><xref ref-type="bibr" rid="article-24538.r22">[22]</xref>.</p>
        <p>
<bold>Infection</bold>
</p>
        <p>The International Society of Heart and Lung Transplantation has classified infections based on their relationship to LVAD&#x000a0;<xref ref-type="bibr" rid="article-24538.r24">[24]</xref>. Infections usually occur at the pump site, pump pocket, or driveline. They typically present with localized warmth and erythema at the pump site, along with fever and leukocytosis. Ultrasound of the local region can diagnose such collections and also guide aspiration. Swabs are helpful in guiding treatment.</p>
        <p>Most commonly, the gram-positive <italic toggle="yes">Staphylococcus aureus</italic> is isolated, but <italic toggle="yes">Enterococcus</italic> and other Staphylococcal species may be present. The most common gram-negative organism is <italic toggle="yes">Pseudomonas aeruginosa&#x000a0;</italic><xref ref-type="bibr" rid="article-24538.r25">[25]</xref>. Aggressive treatment is indicated with the use of appropriate antibiotics to cover the involved pathogen. Surgical revision of the driveline away from the infection may be needed. However, the pump usually needs to be replaced. Surgical debridement may be needed for deeper infections, with the use of omental or muscle flaps or vacuum-assisted closure techniques described <xref ref-type="bibr" rid="article-24538.r26">[26]</xref><xref ref-type="bibr" rid="article-24538.r27">[27]</xref><xref ref-type="bibr" rid="article-24538.r28">[28]</xref>. Infection is associated with significantly increased mortality rates. Hence, severe infections may warrant device explantation with the use of ECMO or cardiac transplantation as definitive treatment.</p>
        <p>
<bold>Neurological</bold>
</p>
        <p>Stroke is one of the most dreaded complications of LVAD placement. Both ischemic and hemorrhagic strokes are known to occur, either immediately postoperatively or after several months&#x000a0;<xref ref-type="bibr" rid="article-24538.r29">[29]</xref>. Strokes more commonly affect the right hemisphere, indicating a cardioembolic source&#x000a0;<xref ref-type="bibr" rid="article-24538.r30">[30]</xref>. Ischemic events have been attributed to partial obstruction of the inflow cannula, deformation of blood in the pump apparatus, outflow graft obstruction, and subtherapeutic anticoagulation or infection. The risk of hemorrhagic stroke is due to anticoagulation. Hence, a fine balance is necessary to achieve optimum anticoagulation.</p>
        <p>
<bold>Arrhythmias</bold>
</p>
        <p>Ventricular arrhythmias are common after the procedure. Placement of the cannula can cause reentrant circuits&#x000a0;<xref ref-type="bibr" rid="article-24538.r31">[31]</xref>. Suction can lead to contact between the cannula and ventricular septum, triggering an arrhythmia. Significant changes in weight or the development of scar tissue can create malposition of the cannula, leading to arrhythmias <xref ref-type="bibr" rid="article-24538.r32">[32]</xref>. Usually, the development of such arrhythmias can be managed by a change in device settings, such as reducing the speed of the LVAD to allow adequate ventricular filling. Management with a variety of medications is usually successful; however, refractory cases require catheter ablation or device exchange.</p>
      </sec>
      <sec id="article-24538.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>LVADs are life-saving in patients with end-stage&#x000a0;cardiac disease. They offer an intermediate to long-term solution for those with HFrEF.&#x000a0;They are most commonly used as a BTT or as DT. The structure and function of these devices have evolved with time, and further developments and advances in this field should help to further reduce the mortality rates from advanced heart failure.</p>
      </sec>
      <sec id="article-24538.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dedicated LVAD setups are required for the management of patients who have received the devices. An integrated interprofessional approach between cardiac surgeons, intensivists, and special LVAD nurses is necessary for adequate monitoring and follow-up of patients to produce the best clinical outcome. Specialty-trained nurses managing patients with LVAD need to be familiar with expected complications and have open communication with the clinicians. The nursing staff should also assist in patient and family education in regard to the device, its purpose, and management requirements. [Level 5]</p>
      </sec>
      <sec id="article-24538.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24538&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24538">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24538/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24538">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24538.s10">
        <title>References</title>
        <ref id="article-24538.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pinsky</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kannel</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of heart failure: the Framingham Study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>4 Suppl A</issue>
            <fpage>6A</fpage>
            <page-range>6A-13A</page-range>
            <pub-id pub-id-type="pmid">8376698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Go</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mozaffarian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roger</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Borden</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Bravata</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fullerton</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hailpern</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Heit</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kissela</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Kittner</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Lichtman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lisabeth</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Magid</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Marelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matchar</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Mohler</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mussolino</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paynter</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Schreiner</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Sorlie</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>MB</given-names>
              </name>
              <collab>American Heart Association Statistics Committee and Stroke Statistics Subcommittee</collab>
            </person-group>
            <article-title>Heart disease and stroke statistics--2013 update: a report from the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Jan</month>
            <day>01</day>
            <volume>127</volume>
            <issue>1</issue>
            <fpage>e6</fpage>
            <page-range>e6-e245</page-range>
            <pub-id pub-id-type="pmid">23239837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Murdoch</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Davie</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Clinical epidemiology of heart failure: public and private health burden.</article-title>
            <source>Eur Heart J</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>19 Suppl P</volume>
            <fpage>P9</fpage>
            <page-range>P9-16</page-range>
            <pub-id pub-id-type="pmid">9886707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rose</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Gelijns</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Heitjan</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Dembitsky</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Tierney</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Levitan</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ronan</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Frazier</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Desvigne-Nickens</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oz</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Poirier</surname>
                <given-names>VL</given-names>
              </name>
              <collab>Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group</collab>
            </person-group>
            <article-title>Long-term use of a left ventricular assist device for end-stage heart failure.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Nov</month>
            <day>15</day>
            <volume>345</volume>
            <issue>20</issue>
            <fpage>1435</fpage>
            <page-range>1435-43</page-range>
            <pub-id pub-id-type="pmid">11794191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Stehlik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dobbels</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kucheryavaya</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Rahmel</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1007</fpage>
            <page-range>1007-22</page-range>
            <pub-id pub-id-type="pmid">19782283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pratt</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Left ventricular assist device management in the ICU.</article-title>
            <source>Crit Care Med</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>158</fpage>
            <page-range>158-68</page-range>
            <pub-id pub-id-type="pmid">24240731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Aaronson</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Naka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>MacGillivray</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Frazier</surname>
                <given-names>OH</given-names>
              </name>
              <collab>HeartMate II Clinical Investigators</collab>
            </person-group>
            <article-title>Use of a continuous-flow device in patients awaiting heart transplantation.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Aug</month>
            <day>30</day>
            <volume>357</volume>
            <issue>9</issue>
            <fpage>885</fpage>
            <page-range>885-96</page-range>
            <pub-id pub-id-type="pmid">17761592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slaughter</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tatooles</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Wozniak</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Ghumman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Frazier</surname>
                <given-names>OH</given-names>
              </name>
              <collab>HeartMate II Investigators</collab>
            </person-group>
            <article-title>Advanced heart failure treated with continuous-flow left ventricular assist device.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Dec</month>
            <day>03</day>
            <volume>361</volume>
            <issue>23</issue>
            <fpage>2241</fpage>
            <page-range>2241-51</page-range>
            <pub-id pub-id-type="pmid">19920051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirklin</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Kormos</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Blume</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Naftel</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Eighth annual INTERMACS report: Special focus on framing the impact of adverse events.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1080</fpage>
            <page-range>1080-1086</page-range>
            <pub-id pub-id-type="pmid">28942782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirklin</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Naftel</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Kormos</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Blume</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Sixth INTERMACS annual report: a 10,000-patient database.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>555</fpage>
            <page-range>555-64</page-range>
            <pub-id pub-id-type="pmid">24856259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jakovljevic</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Yacoub</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Schueler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>MacGowan</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Velicki</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Seferovic</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Hothi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tzeng</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Brodie</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Birks</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Left Ventricular Assist Device as a Bridge&#x000a0;to Recovery for Patients With Advanced Heart Failure.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Apr</month>
            <day>18</day>
            <volume>69</volume>
            <issue>15</issue>
            <fpage>1924</fpage>
            <page-range>1924-1933</page-range>
            <pub-id pub-id-type="pmid">28408022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lund</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aaronson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Patient selection for left ventricular assist devices.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2010</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>434</fpage>
            <page-range>434-43</page-range>
            <pub-id pub-id-type="pmid">20172939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eckman</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bleeding and thrombosis in patients with continuous-flow ventricular assist devices.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Jun</month>
            <day>19</day>
            <volume>125</volume>
            <issue>24</issue>
            <fpage>3038</fpage>
            <page-range>3038-47</page-range>
            <pub-id pub-id-type="pmid">22711669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Piacentino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arepally</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bowles</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Villamizar-Ortiz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>1263</fpage>
            <page-range>1263-9; discussion 1269</page-range>
            <pub-id pub-id-type="pmid">20868825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uriel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pak</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Jorde</surname>
                <given-names>UP</given-names>
              </name>
              <name>
                <surname>Jude</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Susen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vincentelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ennezat</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Cappleman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2010</year>
            <month>Oct</month>
            <day>05</day>
            <volume>56</volume>
            <issue>15</issue>
            <fpage>1207</fpage>
            <page-range>1207-13</page-range>
            <pub-id pub-id-type="pmid">20598466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyle</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Teuteberg</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Slaughter</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Moazami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Frazier</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Heatley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>881</fpage>
            <page-range>881-7</page-range>
            <pub-id pub-id-type="pmid">19716039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potapov</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Stepanenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krabatsch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hetzer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Managing long-term complications of left ventricular assist device therapy.</article-title>
            <source>Curr Opin Cardiol</source>
            <year>2011</year>
            <month>May</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-44</page-range>
            <pub-id pub-id-type="pmid">21460717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kormos</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Teuteberg</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Massey</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Moazami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sundareswaran</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>HeartMate II Clinical Investigators</collab>
            </person-group>
            <article-title>Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2010</year>
            <month>May</month>
            <volume>139</volume>
            <issue>5</issue>
            <fpage>1316</fpage>
            <page-range>1316-24</page-range>
            <pub-id pub-id-type="pmid">20132950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kamdar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Madlon-Kay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colvin-Adams</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pritzker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effects of the HeartMate II continuous-flow left ventricular assist device on right ventricular function.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-15</page-range>
            <pub-id pub-id-type="pmid">20113911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kihara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aomi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koyanagi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effects of milrinone for right ventricular failure after left ventricular assist device implantation.</article-title>
            <source>Heart Vessels</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>69</fpage>
            <page-range>69-71</page-range>
            <pub-id pub-id-type="pmid">11833845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Givertz</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Management of acute right ventricular failure in the intensive care unit.</article-title>
            <source>Curr Heart Fail Rep</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>228</fpage>
            <page-range>228-35</page-range>
            <pub-id pub-id-type="pmid">22805893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scherer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sirat</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Moritz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martens</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal membrane oxygenation as perioperative right ventricular support in patients with biventricular failure undergoing left ventricular assist device implantation.</article-title>
            <source>Eur J Cardiothorac Surg</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>939</fpage>
            <page-range>939-44; discussion 944</page-range>
            <pub-id pub-id-type="pmid">21071240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strueber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Malehsa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haverich</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Successful use of the HeartWare HVAD rotary blood pump for biventricular support.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>140</volume>
            <issue>4</issue>
            <fpage>936</fpage>
            <page-range>936-7</page-range>
            <pub-id pub-id-type="pmid">20478575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feldman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pamboukian</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Teuteberg</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Birks</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lietz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Arabia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bauman</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Buchholz</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dickstein</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>El-Banayosy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elliot</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Grady</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hryniewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kusne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loebe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Massicotte</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Moazami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mohacsi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mooney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Potapov</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Eduardo Rame</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Sorensen</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Strueber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mangi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Petty</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>J</given-names>
              </name>
              <collab>International Society for Heart and Lung Transplantation</collab>
            </person-group>
            <article-title>The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-87</page-range>
            <pub-id pub-id-type="pmid">23352391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Acharya</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Som</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tsui</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>What is the optimum antibiotic prophylaxis in patients undergoing implantation of a left ventricular assist device?</article-title>
            <source>Interact Cardiovasc Thorac Surg</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-14</page-range>
            <pub-id pub-id-type="pmid">22159247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chamogeorgakis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koval</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Smedira</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Starling</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gonzalez-Stawinski</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>Outcomes associated with surgical management of infections related to the HeartMate II left ventricular assist device: Implications for destination therapy patients.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>904</fpage>
            <page-range>904-6</page-range>
            <pub-id pub-id-type="pmid">22759802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shafii</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Chamogeorgakis</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Gonzalez-Stawinski</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Omental flap transposition with intra-abdominal relocation for LVAD pump-pocket infection.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>12</issue>
            <fpage>1421</fpage>
            <page-range>1421-2</page-range>
            <pub-id pub-id-type="pmid">21937245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garatti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giuseppe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Marco</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ettore</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Drive-line exit-site infection in a patient with axial-flow pump support: successful management using vacuum-assisted therapy.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>956</fpage>
            <page-range>956-9</page-range>
            <pub-id pub-id-type="pmid">17845936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsukui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teuteberg</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>McNamara</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Mathier</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cadaret</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kormos</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Cerebrovascular accidents in patients with a ventricular assist device.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>114</fpage>
            <page-range>114-23</page-range>
            <pub-id pub-id-type="pmid">17599496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kato</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Ota</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schulze</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Farr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jorde</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Takayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Naka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Asymmetric pattern of cerebrovascular lesions in patients after left ventricular assist device implantation.</article-title>
            <source>Stroke</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>872</fpage>
            <page-range>872-4</page-range>
            <pub-id pub-id-type="pmid">22207509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogers</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Aaronson</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Slaughter</surname>
                <given-names>MS</given-names>
              </name>
              <collab>HeartMate II Investigators</collab>
            </person-group>
            <article-title>Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2010</year>
            <month>Apr</month>
            <day>27</day>
            <volume>55</volume>
            <issue>17</issue>
            <fpage>1826</fpage>
            <page-range>1826-34</page-range>
            <pub-id pub-id-type="pmid">20413033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24538.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyle</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Arrhythmias in patients with ventricular assist devices.</article-title>
            <source>Curr Opin Cardiol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-8</page-range>
            <pub-id pub-id-type="pmid">22123604</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
